Table 2 Current State of Ototoxicity Monitoring
From: Insight into the current practice of ototoxicity monitoring during cisplatin therapy
| All Malignancies | ||||
|---|---|---|---|---|
|
All malignancies (n = 379) |
Head and Neck (n = 122) | Non-Head and Neck (n = 257) | ||
| N (%) | N (%) | N (%) | P value* | |
| Prior to treatment with cisplatin | ||||
| Counselled about ototoxicity risk | 196 (51.7) | 103 (84.4) | 93 (36.2) | P < .0001 |
| Baseline pre-treatment audiogram ordered | 92 (24.3) | 70 (57.4) | 22 (8.5) | P < .0001 |
| During cisplatin treatment | ||||
| Otologic Complaints | 91 (24) | 51 (41.8) | 43 (16.7) | P < .0001 |
| Treatment changed following otologic complaints | 25 (27.5) | 15 (29.4) | 10 (23.2) | P = .5010 |
| Audiogram ordered during treatment | 17 (4.5) | 6 (5.0) | 11 (4.3) | **P = .7937 |
| Following cisplatin treatment | ||||
| Otologic Complaints (total) | 130 (34.2) | 75 (61.5) | 55 (40) | P < .0001 |
| 1-month post-treatment audiogram | 20 (7.8) | 13 (10.6) | 7 (2.7) | **P = .0024 |
| 3-month post-treatment audiogram | 13 (5.1) | 11 (9.0) | 2 (0.8) | **P = .0001 |
| 6-month post-treatment audiogram | 16 (6.2) | 12 (9.8) | 4 (1.6) | **P = .0004 |
| Audiogram or Otolaryngology Consult 6–24 months post treatment | 38 (15) | 22 (18) | 16 (6.2) | P = .0003 |